Attribution of deaths following cancer treatment.
نویسندگان
چکیده
Government agencies provide regular reports on progress in the fight against cancer, and these reports are viewed with great interest by researchers and by the media (1). The primary measures of the cancer burden are cancer incidence rates and cancer mortality rates. The latter are derived from state death certificates, which are completed by physicians, medical examiners, coroners, and funeral directors, and collated by the National Center for Health Statistics (NCHS) (2). The data from death certificates are compiled using the World Health Organization schema to determine the underlying cause of death. The classification rules are changed periodically; most recently in 1999 with the adoption of the Tenth Revision of the International Statistical Classification of Diseases and Related Health Problems (ICD) (3). This general approach leads to the designation of a unitary “underlying” cause for each death. In practice, a death may be precipitated by multiple causes. Recently, the NCHS has developed a system for processing multiple classifications, including the use of relevant free text from the death certificate (2). However, the National Cancer Institute continues to report death rates using deaths for which cancer is designated as the sole underlying cause. In this issue of the Journal, Welch and Black (4) raise the concern that cancer death rates are systematically underestimated, in that many patients who die as a result of cancer treatment do not have cancer recorded as the underlying cause of death. The authors assembled data on the reported cause of death for all patients in the Surveillance, Epidemiology, and End Results (SEER) program from 1994 through 1998 who died within 1 month of cancer-directed surgery for one of 19 common solid tumors. They found that for 41% of these deaths, the cause was not attributed to cancer. The authors speculate that cancer treatment is the probable underlying cause for essentially all of these deaths and, as a result, the cancer mortality rate is underestimated by 0.9%. Welch and Black (4) also suggest that many deaths subsequent to 1 month after cancer-directed surgery may be similarly miscoded, leading to further underestimation. We note that the terminology related to death rates can be confusing. The term “cancer mortality rate” is used conventionally to represent a cancer death rate in the total population— where the denominator includes all people in the population with or without the cancer of interest. Thus, the metric is comparable to the “cancer incidence rate” in the population. By contrast, the term “cancer survival” usually refers to the mortality experience (survival rather than death) among patients with a cancer diagnosis. However, in studies of postoperative outcomes, the terms “operative mortality” or “surgical mortality” are often used, although the denominator includes only cancer surgery recipients. To calibrate their calculations throughout their article, Welch and Black (4) used population-based rates. The misattribution of cancer deaths is a long-studied issue (5–8). Welch and Black (4) appear to be especially concerned about systematic underestimation in the context of greater use of cancer screening tests. Greater use of cancer-directed surgery in patients with small, early-stage lesions leading to, presumably, more deaths following a cancer diagnosis that are not attributed to cancer could exaggerate the benefits of screening. Welch and Black (4) propose that for all deaths following cancer treatment—including radiotherapy, chemotherapy, and surgery— cancer should be designated as the underlying cause of death. They propose the development of “simple” though arbitrary rules, such as the designation of any death within 1 month of treatment as a cancer death. Although we agree that continued efforts to refine and improve the classification and reporting of cancer mortality statistics are worthwhile, and indeed are being pursued in the government agencies responsible for reporting vital statistics, the specific ideas proposed by Welch and Black (4) appear to us to be impractical and may themselves introduce inaccuracies. Consider first the proposal to designate all deaths within 1 month of surgery as cancer deaths, and take, as an example, the use of radical prostatectomy for prostate cancer. We know that the 1-month death rate following this procedure in men over 65 years of age is 0.49% (9). Welch and Black (4) would, by their convention, designate all of these deaths as cancer deaths. However, in an elderly population of this nature (i.e., men over age 65 years), the underlying force of mortality is strong. In fact, using death rates for men in the United States from the NCHS (2), adjusted to the age distribution of the surgery patients receiving prostatectomy, the underlying probability of death in any given month for this cohort of men is 0.28%. That is, of the operative deaths that occur, 57% are expected in the absence of the procedure. When viewed from this context, the observation by Welch and Black (4) that 75% of deaths within 1 month of prostatectomy are not attributed to cancer appears only modestly exaggerated. To be sure, patients who receive surgery are a selected group, because surgeons will generally not operate on patients who appear to be at imminent risk of death or are otherwise seriously medically compromised. Nonetheless, many deaths do occur suddenly and unpredictably. For procedures with much higher operative mortality than prostate cancer— such as pancreatectomy, esophagectomy, or lung resection—we agree that a higher proportion of the operative deaths are likely to be caused by the procedure. However, these are among the sites for which the reclassification proposed by Welch and Black (4) would have the least impact, because relatively few incident cases receive surgery, and the mortality rate of the disease is high relative to the incidence rate. Welch and Black (4) also propose greater efforts to educate individuals who prepare death certificates on basic strategies for ensuring that treatment-related deaths are attributed to cancer. However, this would appear to be a daunting and complex task, with uncertain payoff in improved accuracy, given the vast num-
منابع مشابه
Colorectal and Vulvar Synchronous Cancer: A Case Report
Synchronous cancer is referred to two or more histological distinct malignancies diagnosed during the same hospital admission. Globally more than 1 million people get colorectal cancer yearly resulting in about 0.5 million deaths. Vulvar cancer is the fourth most common gynecologic cancer (following the corpus uterine cancer, cancer of ovary and cervix) and comprises only 4 percent of malignanc...
متن کاملAn Overview of the Epigenetic Modifications of Gene Expression in Tumorigenesis
The five leading causes of cancer-related deaths are lung (1,760,000 deaths), colorectal (862,000 deaths), stomach (783,000 deaths), liver (782,000 deaths), and breast (627,000 deaths) cancers. Epigenetic changes can alter chromatin compaction, leading to the regulation of geneexpression without changing the primary DNA sequence.Epigenetic mechanisms are normally involved incellular processes s...
متن کاملProstate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection.
Major clinical trials using prostate-specific antigen (PSA) as the screening test to detect localized early-stage prostate cancer and to attempt to change its natural history with early intervention have yielded conflicting interpretations. The US Prostate, Lung, Colorectal, and Ovarian (US PLCO) cancer screening trial concluded that PSA-based screening conferred no meaningful survival benefit,...
متن کاملMedullary Thyroid Cancer: A Review
Thyroid cancer is a malignancy of the thyroid parenchymal cells. There are four main types of thyroid cancer: papillary thyroid cancer (PTC), follicular thyroid cancer (FTC), anaplastic thyroid carcinoma (ATC), and Medullary thyroid carcinoma (MTC). Medullary thyroid cancer (MTC) is a rare neuroendocrine tumor of the thyroid gland derived from parafollicular C-cells that produce calcitonin (CT...
متن کاملChronic myeloid leukemia following colon cancer treatment: A case report and literature review
Background: Solid tumors may occur in 3% of the patients with chronic myeloid leukemia (CML). In this paper, we presented a case of CML following treatment of colon cancer. Case Presentation: A 25 year old man was diagnosed of adenocarcinoma of rectosigmoid treated with fluorouracil-based chemotherapy. Following relapse, he received florouracil, oxaliplatin and irinotecan during the next year. ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Journal of the National Cancer Institute
دوره 94 14 شماره
صفحات -
تاریخ انتشار 2002